<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412786</url>
  </required_header>
  <id_info>
    <org_study_id>UR1534</org_study_id>
    <nct_id>NCT03412786</nct_id>
  </id_info>
  <brief_title>Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases</brief_title>
  <official_title>A Phase I Study of the Bcl-XL_42-CAF09b Vaccine to Test Safety and Immunological Effect in Patients With Prostate Cancer With Lymph Node Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase I study, patients with hormone-sensitive Prostate Cancer (PC) and lymph node&#xD;
      metastases are treated with the cancer vaccine Bcl-xl_42-CAF09b. The aim of the study is to&#xD;
      clarify the safety and toxicity of the vaccine and also the immunological effect.&#xD;
&#xD;
      The vaccine Bcl-xl_42-CAF09b is composed of the peptide Bcl-xl_42 and the adjuvant CAF09b.&#xD;
      The B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer&#xD;
      cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of&#xD;
      cancerous diseases. Bcl-xl_42 is a peptide fragment of the full protein and preclinical&#xD;
      studies have shown that vaccination with this peptide (Bcl-xl) can activate the immune system&#xD;
      and thereby lead to the death of cancer cells. In order to improve the activation of the&#xD;
      immune system, adjuvant CAF09b is added; Preclinical studies have shown that special&#xD;
      intraperitoneal (IP) injections of CAF09b improve the activation of the immune system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      In this Phase I study, patients with hormone-sensitive Prostate Cancer (PC) and lymph node&#xD;
      metastases are treated with the cancer vaccine Bcl-xl_42-CAF09b. The aim of the study is to&#xD;
      clarify the safety and toxicity of the vaccine and also the immunological effect.&#xD;
&#xD;
      Patients included should be on Bicalutamid treatment upon inclusion. The vaccine&#xD;
      Bcl-xl_42-CAF09b is composed of the peptide Bcl-xl_42 and the adjuvant CAF09b. The B-cell&#xD;
      lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability&#xD;
      to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous&#xD;
      diseases. Bcl-xl_42 is a peptide fragment of the full protein and preclinical studies have&#xD;
      shown that vaccination with this peptide (Bcl-xl) can activate the immune system and thereby&#xD;
      lead to the death of cancer cells.&#xD;
&#xD;
      In order to improve the activation of the immune system, adjuvant CAF09b is added;&#xD;
      Preclinical studies have shown that special intraperitoneal (IP) injections of CAF09b improve&#xD;
      the activation of the immune system.&#xD;
&#xD;
      The CAF09 adjuvant has been developed by Statens Serum Institut (SSI). It is a&#xD;
      three-component adjuvant system, composed of cationic liposomes (DDA-MMG1) with complex bound&#xD;
      synthetic double-stranded RNA (Poly(I:C)2). The adjuvant was developed as a means to induce&#xD;
      cytotoxic CD8+ T-cell responses against vaccine antigens and intended for use in vaccines&#xD;
      against disease targets such as cancers, human immunodeficiency virus or Hepatitis C virus.&#xD;
      The Poly(I:C) component has previously been in clinical studies as a cancer treatment.&#xD;
      Poly(I:C) is known for its pyrogenic activity but upon formulation in the cationic liposome&#xD;
      system, CAF09, the pyrogenic effect is significantly reduced.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      20 patients will be included in this phase I trial. 10 patients will be included in arm A and&#xD;
      10 patients in arm B. Arm a will recieve 3 vaccines every second week IM and thereafter 3&#xD;
      vaccines every second week IP. Arm B will first receive 3 vaccines every second week IP and&#xD;
      thereafter every second week IM. All 20 patients will recieve 6 vaccines all in all. This is&#xD;
      not randomized - the first 10 patients included will be in arm A and the last 10 patients&#xD;
      included will be in arm B.&#xD;
&#xD;
      Patients will be followed with clinical controls every second week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Not a randomized study. The first 10 patients included will be treated in arm A - the last 10 will be treated in arm B.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number and type of reported adverse events</measure>
    <time_frame>0-30 weeks</time_frame>
    <description>Determine the safety of the Bcl-XL_42-CAF09b vaccine for patients with prostate cancer with lymph node involvement who are on Bicalutamid treatment by reporting adverse events according to CTCAE v. 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related immune responses</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To evaluate the immunological impact of the treatment in both arm A and arm B. Elispot and tetramer staining methods will be Applied to identify Bcl-XL_42 peptide specific T cells in the blood over time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: IM followed by IP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: IP followed by IM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bcl-Xl_42-CAF09b vaccine</intervention_name>
    <description>The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion</description>
    <arm_group_label>Arm A: IM followed by IP</arm_group_label>
    <arm_group_label>Arm B: IP followed by IM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Histologically Verified Adenocarcinoma Prostatae&#xD;
&#xD;
          3. Diagnostic and / or histologically verified lymph node metastases&#xD;
&#xD;
          4. ECOG Performance Status ≤2&#xD;
&#xD;
          5. Primary anti-androgen treatment started&#xD;
&#xD;
          6. Adequate haematological, renal and hepatic function:&#xD;
&#xD;
               1. Neutrophil granulocytes ≥ 1.5 x 109 / l&#xD;
&#xD;
               2. Platelet counts ≥ 100 x 109 / l&#xD;
&#xD;
               3. hemoglobin ≥ 5.6 mmol / l&#xD;
&#xD;
               4. Serum creatinine ≤ 1.5 times upper normal limit&#xD;
&#xD;
               5. AST or ALAT ≤ 2.5 times upper normal limit&#xD;
&#xD;
               6. serum bilirubin ≤ 1.5 times upper normal limit&#xD;
&#xD;
               7. Alkaline phosphatase ≤ 2.5 times upper normal limit&#xD;
&#xD;
               8. INR &lt;1.5 / PP &lt;40&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Verified bone or visceral metastases&#xD;
&#xD;
          2. Serious allergy or previous anaphylactic reactions&#xD;
&#xD;
          3. Known hypersensitivity to any of the active substances or to any of the excipients.&#xD;
&#xD;
          4. Other malignant disease within the last three years, rendering planocellular and&#xD;
             basocellular skin carcinoma&#xD;
&#xD;
          5. Known infection with HIV, hepatitis B and C virus, regardless of whether the infection&#xD;
             is kept calm with medical treatment&#xD;
&#xD;
          6. Severe medical disorder, severe asthma, severe COPD, poorly regulated cardiovascular&#xD;
             disease or diabetes&#xD;
&#xD;
          7. Active autoimmune disease, e.g. autoimmune neutropenia / thrombocytopenia or hemolytic&#xD;
             anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, goodpasture&#xD;
             syndrome, Addison's disease, Hashimoto's thyroiditis, active grave disease, morbus&#xD;
             chrohn or ulcerative colitis&#xD;
&#xD;
          8. Major gastrointestinal surgical procedures within the last 3 months&#xD;
&#xD;
          9. Previous treatment with other cancer vaccine&#xD;
&#xD;
         10. Concomitant immunosuppressive treatment including prednisolone and methotrexate&#xD;
&#xD;
         11. Ongoing anticoagulant treatment (treatment with acetylsalicylic acid and clopidogrel&#xD;
             is allowed)&#xD;
&#xD;
         12. Psychiatric disease which, according to the investigator's discretion, may affect&#xD;
             compliance&#xD;
&#xD;
         13. Co-administration with other experimental drugs.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inge Marie svane</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IngeMarie Svane</last_name>
    <phone>38682131</phone>
    <email>inge.marie.svane@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge Marie Svane, Prof., MD</last_name>
      <phone>+4538683868</phone>
      <email>inge.marie.svane@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Julie W Kjeldsen, MD</last_name>
      <phone>+4538683868</phone>
      <email>julie.westerlin.kjeldsen@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 2, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Inge Marie Svane</investigator_full_name>
    <investigator_title>Prof., MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

